Breaking AI & Tech News Analyzed

A Guardian investigation has shed light on the dark reality of child sex trafficking on Facebook and Instagram, prompting a landmark lawsuit against Meta. The tech giant has been fined $375m in a New Mexico court case, highlighting its failure to prevent criminal exploitation on its platforms.The investigation, led by reporter Katie McQue, began with a tip-off about surging child sexual abuse trafficking in the US. It uncovered evidence of traffickers using Facebook Messenger and private Instagram accounts to target, groom, and exploit children. Meta was found to be struggling to prevent these crimes, despite warnings from experts and law enforcement.The probe involved extensive research, including analysis of court documents and interviews with former Meta contract workers. These workers reported that their efforts to flag and escalate possible child trafficking often went unaddressed, and harmful content was rarely removed.The investigation's findings were published in April 2023, revealing how Facebook and Instagram had become marketplaces for child sex trafficking. The case was cited in a US supreme court amicus brief, and New Mexico's office of the attorney general filed a lawsuit against Meta for failing to protect children.The lawsuit went to trial, and Meta lost the court battle in March, being ordered to pay $375m in civil penalties. The company has said it will appeal the ruling, maintaining its stance on protecting teens online.This case marks a significant milestone in the ongoing scrutiny of social media platforms' role in combating child exploitation. Meta faces further trials, including one with a coalition of 33 attorneys general alleging the company designed features that 'purposefully addict children and teens.'

Online betting platform Polymarket has come under fire for allowing users to wager on the fate of US pilots shot down in Iran. The platform has since halted the bets and promised to investigate how they were allowed to happen. The controversy began when US Representative Seth Moulton publicly denounced the practice, calling it 'DISGUSTING' that people were betting on the pilots' rescue while search efforts were still underway. Moulton, a veteran of the US Marine Corps, expressed his outrage on social media platform X. The incident involved an F-15E Strike Eagle jet shot down by Iranian military forces, with one pilot rescued within seven hours and the other rescued on Sunday, as announced by Donald Trump on his Truth Social platform. Polymarket initially allowed users to bet on the timing of the rescues, with most wagers predicting they would occur by Saturday. However, after Moulton's criticism, the platform quickly removed the market, stating it did not meet their integrity standards and vowed to investigate. Moulton did not stop there, calling on Polymarket to deactivate hundreds of other war-related wagers, accusing the company of having 'severely lacking' integrity standards. He also mentioned that Donald Trump Jr, the president's oldest son, is an investor in Polymarket, which Moulton referred to as a 'dystopian death market'. This incident is not the first time Polymarket has faced scrutiny. In March, some users generated international headlines by sending threatening messages to an Israeli journalist after betting on a missile strike near Jerusalem. The controversy surrounding prediction markets like Polymarket has drawn congressional attention, with lawmakers introducing proposals to ban betting on certain topics, including sports, government actions, and events 'ripe for rigging'. US Senator Chris Murphy stated that such markets risk 'corrupting the soul of America' by turning life-and-death events into financial products.

Two weeks after the United States and Israel entered a direct conflict with Iran, the White House faced mounting criticism that the war would drive up fuel costs and anger voters. Former President Donald Trump attempted to calm concerns on Truth Social, noting that the United States is the world’s largest oil producer and that higher prices translate into higher revenues for American companies. Now, five weeks into the hostilities, the reality is becoming clear: defense contractors and oil companies are the primary beneficiaries of the escalating energy market. The Department of Defense announced that Boeing will partner with Lockheed Martin to triple U.S. production of missile seekers, a move that sent Lockheed Martin’s stock up 25% since the start of the year. The announcement also lifted Boeing’s share price, underscoring how wartime procurement is boosting aerospace valuations. At the same time, Iran’s continued blockade of the Strait of Hormuz—through which roughly one‑fifth of global oil and gas flows—has pushed U.S. crude from $65 to over $110 per barrel in just a month. Pump prices have mirrored this surge, breaking the $4‑a‑gallon barrier for the first time since 2022. Oil majors have responded with sharp stock gains; ExxonMobil, Shell and Chevron have each risen more than 20% year‑to‑date. According to market‑research firm Rystad Energy, U.S. oil producers stand to earn an additional $63 billion as barrels trade above $100. “Oil prices in March have been materially higher than anyone expected, delivering a windfall for the vast majority of U.S. energy companies,” said Leo Mariani, senior analyst at Roth Capital Partners. The last comparable price shock occurred in 2022 after Russia’s invasion of Ukraine, when U.S. gasoline peaked at $5 per gallon and inflation surged to 9%. That episode generated $916 billion in global oil‑and‑gas profits, with U.S. firms accounting for $281 billion. Chevron’s subsequent $75 billion stock‑buyback program—seven times its prior year’s amount—illustrates how quickly companies can translate price spikes into shareholder returns. Research by economists Gregor Semieniuk and Isabella Weber revealed that in 2022, 50% of oil‑company profits went to the top 1% of Americans, while the bottom half of the wealth distribution captured just 1% of those gains. Analysts warn that the current conflict could generate even larger windfalls because it has damaged actual production capacity in the Middle East, not merely reshuffled supply. “You’re benefiting a lot more from higher prices than you are from lost production,” Mariani noted, emphasizing the outsized profit potential. Even if hostilities cease, restoring pre‑conflict output in the region may take months, prolonging the supply crunch. As senior fellow Clay Seagle of the Center for Strategic and International Studies explains, the current situation differs from 2022: “Now we’re dealing with a much more severe supply event because the oil has been actually removed from the market.” Prolonged high prices could eventually curb demand, as consumers and businesses seek alternatives—a shift seen after the 1970s oil shocks when the U.S. moved away from oil‑generated electricity. Nonetheless, many sectors remain vulnerable: diesel, a key fuel for trucks and aircraft, has risen 40%, and airline stocks such as United and American have fallen more than 15% since the year began. Moreover, disruptions to liquefied natural gas (LNG) production threaten fertilizer supplies essential for agriculture. Semieniuk cautions that “we’re approaching the kinds of disruption levels we saw in 2022, and with that, the kinds of profits that we saw there. If this takes longer, it’s going to surpass that.”

Eight OPEC+ participants have consented to raise daily oil‑production quotas by 206,000 barrels for May, a modest adjustment given that several key producers are constrained by the US‑Israeli conflict with Iran that has sealed the Strait of Hormuz.The strategic waterway has been blocked since late February, halting shipments from the core OPEC+ exporters Saudi Arabia, the United Arab Emirates, Kuwait and Iraq, thereby tightening global supply.During a virtual session, the eight members—Saudi Arabia, Russia, Iraq, the UAE, Kuwait, Kazakhstan, Algeria and Oman—endorsed the May quota increase and reiterated their commitment to monitor market dynamics closely.The joint statement highlighted ongoing vigilance over market conditions and expressed concern that attacks on energy infrastructure make restoration costly and time‑intensive, further limiting supply availability.Although the increase accounts for less than 2% of the volume lost due to the Hormuz closure, OPEC+ sources told Reuters the decision signals a willingness to expand output once the strait reopens.Crude prices have surged to around $120 per barrel, a four‑year high, driving up transport‑fuel costs worldwide.JPMorgan warned that if the blockage persists into mid‑May, oil could breach $150 a barrel, an unprecedented level.The May adjustment mirrors the April decision made on March 1, yet the conflict is estimated to have removed between 12 and 15 million barrels per day—approximately 15% of global supply.Iran has allowed certain regional vessels to navigate the strait; Iraqi crude was observed transiting, and Oman is conducting talks with Tehran to facilitate smoother passage.U.S. President Donald Trump has threatened to expand attacks on Iranian civilian infrastructure, including bridges and power plants, if the Strait of Hormuz does not reopen by Monday.

The UK government has announced that it will not pursue a ban on foie gras imports and will not restrict fur imports, citing the need to prioritize trade agreements with the EU. This decision reverses a previous commitment to restrict the import of these products, which are often associated with animal cruelty.The move has been criticized by animal welfare charities, who argue that the UK's high animal welfare standards should not be compromised for the sake of trade agreements. The RSPCA and other organizations have expressed disappointment and concern about the impact on animal welfare.The UK had previously banned fur farming in 2000 and the production of foie gras in 2006, but imports of these products have continued. The EU has made it clear that it will not allow member states to ban each other's products on animal welfare grounds, which has limited the UK's ability to restrict imports.The decision is seen as a significant concession to the EU as the UK seeks to secure a trade deal. The government has stated that it is prioritizing economic growth and has set up a working group to examine the fur industry.Animal welfare charities and some businesses are urging the government to reconsider its decision and maintain its commitment to banning these products. Some restaurants and shops have already removed foie gras from their menus and shelves, citing concerns about animal welfare.

The Accelerator's Withdrawal: A Signal of Loss of ConfidenceDelve's relationship with Y Combinator has officially ended following a series of damaging allegations regarding compliance and data security. This severance marks a significant blow to the startup's credibility, compounded by the distancing actions of other major investors like Insight Partners.The Catalyst: Anonymous Allegations and Data BreachesThe controversy stems from an anonymous Substack campaign by "DeepDelver," which accused the company of misleading clients about regulatory compliance and passing off open-source tools as proprietary technology. These claims were further fueled by a security researcher's ability to access sensitive Delve data and a malware incident involving a customer, LiteLLM.YC's Response: Delve was removed from the accelerator's portfolio directory, with COO Selin Kocalar confirming the split on X.Insight Partners: The firm initially deleted posts about its investment but later restored the primary blog entry.The Defense: A Coordinated Attack or Operational Failure?In a bid to set the record straight, Delve's leadership team, including CEO Karun Kaushik, claims the attacks are a coordinated smear campaign orchestrated by an attacker who exfiltrated internal data. They argue that the "evidence points to a malicious attack rather than a genuine whistleblower."However, the company also acknowledged "growing too fast and falling short of our own standard." To mitigate the damage, Delve has hired a cybersecurity firm, offered complimentary re-audits to customers, and clarified that their open-source usage is compliant with Apache 2.0 licensing.Future Outlook: Rebuilding Trust in a Fragile EcosystemThe departure from Y Combinator suggests that the startup's growth trajectory is now in jeopardy. For a compliance-focused company, trust is the primary currency; the current allegations threaten to devalue this currency permanently. The coming months will determine if Delve can survive this reputational crisis or if it will become a cautionary tale in the compliance tech sector.

The US labor market demonstrated unexpected strength in March, with the unemployment rate dropping to 4.3% despite concerns over economic instability and the ongoing conflict with Iran. According to the US Bureau of Labour Statistics, non-farm payrolls grew by 178,000 jobs in March, rebounding from a downwardly revised loss of 133,000 jobs in February.The healthcare sector led the gains, adding 76,000 jobs in March, significantly higher than the 29,000 average monthly increase over the last year. This surge follows a large-scale nursing strike that ended on February 24, which had temporarily removed over 30,000 healthcare workers from payrolls.The construction sector also saw notable growth, with 26,000 jobs added in March. Additionally, the transportation and warehousing sector grew by 21,000 jobs over the previous month, although it has experienced an overall loss of 139,000 jobs since February 2025.In contrast, the federal government, the largest employer in the US, continued to shrink, cutting 18,000 federal employee positions in March. This marks a 355,000 job decline from the same period last year.The White House has praised the jobs report as evidence that President Trump's policies are stimulating the domestic economy. Kush Desai, White House deputy press secretary, stated that the March jobs report 'blew out expectations' with strong construction job growth and a surge in manufacturing job creation.However, experts warn that the impact of the US conflict with Iran, dubbed Operation Epic Fury, is not yet fully reflected in the job numbers. Economists at JPMorgan cautioned that negative payroll readings could become more common, and Angela Hanks, chief of policy programmes at The Century Foundation, noted that wage growth has stalled, and oil prices are skyrocketing, threatening to weaken the job market.The economic uncertainty is also affecting US consumers, with the University of Michigan's consumer sentiment survey dropping by 6% in March to its lowest level since December 2025. Furthermore, the average price for a gallon of petrol has increased to $4.09 ($1.08 per litre), up from $3.10 ($0.82 per litre) this time last month.

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

President Donald Trump announced on Truth Social that Pam Bondi is being removed as Attorney General, ending a contentious 14‑month stint at the Justice Department. Bondi, who described her upcoming shift to the private sector as a "transition," will leave the post within the next month. In a rapid reshuffle, Trump elevated Deputy Attorney General Todd Blanche—who previously served as the former president’s criminal‑defense lawyer—to acting attorney general. The president also hinted that EPA Administrator Lee Zeldin could become the permanent replacement, signaling a continued preference for close allies in key legal roles. Bondi’s ouster follows a series of high‑profile controversies. Most notably, her management of the Jeffrey Epstein files drew intense scrutiny. After promising full transparency, the Justice Department released heavily redacted documents that failed to satisfy public and congressional demands for a "client list" and other evidence. Critics, including victims’ attorney Gloria Allred, called her departure "long overdue" for mishandling the files. Beyond the Epstein saga, Bondi struggled to deliver the political prosecutions Trump expected. Efforts to pursue former FBI Director James Comey and other officials linked to investigations of the president stalled or collapsed, fueling Trump’s frustration that she was not "weaponising" the department aggressively enough against his perceived enemies. Bondi, a former Florida attorney general and the state’s first female AG, built a reputation on tough‑on‑crime initiatives such as combating human trafficking and cracking down on "pill mills." However, her limited involvement in the original Epstein non‑prosecution deal and her heated exchange with a Democratic lawmaker—where she called him a "washed‑up loser"—further eroded confidence in her leadership. The White House confirmed that Bondi’s private‑sector role will be announced "in the near future," while Blanche issued a statement on X thanking Trump for the trust placed in him and pledging to "continue backing the blue, enforcing the law, and keeping America safe." Congressional oversight intensifies as the House Oversight Committee had scheduled Bondi to appear before it on April 14 to answer questions about the Epstein documents. With her exit, committee chair James Comer said Republicans would deliberate whether to pursue the subpoena, while Democrats, led by Robert Garcia, insist she "will not escape accountability." Reactions span the political spectrum: Democrats such as Senator Elizabeth Warren denounced the DOJ under Bondi as a "cesspool of corruption," whereas Republican Senator Chuck Grassley praised her responsiveness to oversight and noted a decline in violent crime during her tenure. Republican Thomas Massie urged the next AG to release all Epstein files and pursue arrests. As the administration searches for a permanent attorney general, the choice between Blanche and Zeldin will signal how closely Trump intends to align the Justice Department with his political agenda moving forward.